10.3945/ajcn.115.119321 20
VermaS,PoulterNR,BhattDL,BainSC,BuseJB,LeiterLA,etal.Effects of liraglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus with or without history of myocardial infarction or stroke: Post hoc analy- sis from the leader trial.Circulation.2018;138:288494, .MannJFE,FonsecaV,MosenzonO,RazI,GoldmanB,IdornT,etal.Effects of liraglutide versus placebo on cardiovascular events in patients with type 2 dia- betes mellitus and chronic kidney disease: Results from the LEADER trial.Circulation.2018;138:290818, VermaS,BhattDL,BainSC,BuseJB,MannJFE,MarsoSP,etal.Effect of liraglutide on cardiovascular events in patients with type 2 diabetes mellitus and polyvascular disease.Circulation.2018;137:217983, Funding This work was supported by the Instituto de Salud Carlos III (PI19/01375) co-financed with FEDER programme fund
PMID: 32292042
Univariately, no differences in 30% and 50% responder-rate were seen between the groups (Supplementary Table 1)
Lack of benefit of iron chelation in early Parkinson's disease
Your products are incredible, when they are used by following your beautiful guidelines
